Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

Forty-nine protease inhibitor (PI)-experienced but amprenavir (APV)-naïve patients experiencing virological failure were treated with ritonavir (RTV) (100 mg twice a day [b.i.d.]) plus APV (600 mg b.i.d.). Patients responded to therapy with a median viral load decrease of −1.32 log(10) by week 12. T...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Marcelin, Anne-Geneviève, Lamotte, Claire, Delaugerre, Constance, Ktorza, Nadine, Ait Mohand, Hocine, Cacace, Raquel, Bonmarchand, Manuela, Wirden, Marc, Simon, Anne, Bossi, Philippe, Bricaire, François, Costagliola, Dominique, Katlama, Christine, Peytavin, Gilles, Calvez, Vincent
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2003
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC151735/
https://ncbi.nlm.nih.gov/pubmed/12543665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.47.2.594-600.2003
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items